Physician profile
Javier C Corral
NPI 1558301002
$2,579.80
in general payments reported to CMS, 2019-2025
31 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $186 · 2021: $211 · 2022: $199 · 2023: $280 · 2024: $575 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.11 |
| Education | $116.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $387.71 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $372.30 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $200.22 | 2019-2025 | Rybrevant, Darzalex, Balversa |
| Merck Sharp & Dohme LLC | $188.91 | 2020-2025 | Keytruda, Welireg, Keytruda Qlex |
| Gilead Sciences, INC. | $181.22 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $140.26 | 2020-2025 | Enhertu |
| Eisai INC. | $121.35 | 2019 | |
| Astellas Pharma US INC | $121.33 | 2019-2024 | Cresemba, Padcev, Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $98.26 | 2022-2025 | Gattex |
| Pfizer INC. | $82.88 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $80.96 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $70.19 | 2020-2023 | |
| Array Biopharma INC | $53.43 | 2022-2024 | Mektovi, Braftovi, Tukysa |
| Puma Biotechnology, INC. | $45.25 | 2021-2025 | |
| Celgene Corporation | $45.21 | 2023-2024 | Reblozyl |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.96 | 2023 | Lumakras, Xgeva |
| Lilly USA, LLC | $42.69 | 2024 | Retevmo, Verzenio, Jaypirca |
| Beigene USA, INC. | $37.99 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $36.98 | 2021-2022 | |
| Genmab U.S., INC. | $32.54 | 2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $26.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.40 | 2025 | |
| Kyowa Kirin, INC. | $22.26 | 2025 | |
| Seagen INC. | $20.60 | 2021 | |
| Tersera Therapeutics LLC | $17.61 | 2023 | Quzyttir |
| Tempus Ai, INC | $17.52 | 2024 | |
| Adaptive Biotechnologies Corporation | $15.90 | 2023 | Clonoseq |
| Genentech USA, INC. | $15.08 | 2019 | |
| Beone Medicines USA, INC. | $14.87 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $13.56 | 2019 | |
| Verastem, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Corral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.